Received May 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Administration of Havrix adult dose to a 17 year-old patient; received the adult dose of Havrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 17-year-old female patient who received HAV (Havrix adult) for prophylaxis. On an unknown date, the patient received the 1st dose of Havrix adult. On an unknown date, an unknown time after receiving Havrix adult, the patient experienced adult use of a child product (Verbatim: Administration of Havrix adult dose to a 17 year-old patient) and overdose (Verbatim: received the adult dose of Havrix). The outcome of the adult use of a child product and overdose were not applicable. Additional Information: GSK Receipt Date: 28-APR-2025 The pharmacist reported that a month ago on March 2025, a 17 year-old patient received the adult dose of Havrix as a first dose, which led to adult use of a child product and overdose. Patient was going to the military so she had been taking all vaccination again, such as IPV, Varicella, etc. The Healthcare professional advised her doctor about this procedure. No adverse effects had been reported to date. The Vaccine Administration Facility is the same as Primary Reporter.